Free Trial

Eterna Therapeutics Q1 2023 Earnings Report

Eterna Therapeutics logo
$0.31 -0.02 (-7.08%)
As of 02/21/2025 04:00 PM Eastern

Eterna Therapeutics EPS Results

Actual EPS
-$1.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eterna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eterna Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Eterna Therapeutics Earnings Headlines

Eterna appoints Zeldis, Sather to scientific advisory board
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
Eterna Therapeutics Appoints Dr. Elena Ratner To Board Of Directors
See More Eterna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eterna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eterna Therapeutics and other key companies, straight to your email.

About Eterna Therapeutics

Eterna Therapeutics (NASDAQ:ERNA), a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Eterna Therapeutics Profile

More Earnings Resources from MarketBeat